- Home
- RLAY
as 02-21-2025 4:00pm EST
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
Upcoming Earnings Alert:
Get ready for potential market movements as Relay Therapeutics Inc. RLAY prepares to release earnings report on 28 Feb 2025.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 811.8M | IPO Year: | 2020 |
| Target Price: | $20.11 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.50 - $10.89 | Next Earning Date: | 02-28-2025 |
| Revenue: | $10,006,000 | Revenue Growth: | -61.22% |
| Revenue Growth (this year): | -37.95% | Revenue Growth (next year): | -77.38% |
Stock Insider Trading Activity of Relay Therapeutics Inc. (RLAY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Patel Sanjiv | RLAY | President and CEO | Feb 11 '25 | Sell | $3.78 | 215,506 | $818,399.50 | 883,089 | |
| Adams Brian | RLAY | Chief Legal Officer | Jan 28 '25 | Sell | $4.53 | 54,479 | $247,871.66 | 406,270 | |
| Catinazzo Thomas | RLAY | Chief Financial Officer | Jan 28 '25 | Sell | $4.56 | 58,936 | $268,338.85 | 265,473 | |
| Rahmer Peter | RLAY | See remarks | Jan 28 '25 | Sell | $4.53 | 45,464 | $204,752.54 | 307,081 | |
| Patel Sanjiv | RLAY | President and CEO | Jan 21 '25 | Sell | $4.70 | 375,000 | $1,762,500.00 | 883,089 | |
| Rahmer Peter | RLAY | See remarks | Jan 2 '25 | Sell | $4.30 | 80,909 | $345,571.70 | 307,081 | |
| Bergstrom Donald A | RLAY | President, R&D | Dec 27 '24 | Sell | $4.38 | 657 | $2,877.66 | 520,088 | |
| Adams Brian | RLAY | Chief Legal Officer | Dec 27 '24 | Sell | $4.38 | 299 | $1,309.62 | 406,270 | |
| Catinazzo Thomas | RLAY | Chief Financial Officer | Dec 27 '24 | Sell | $4.40 | 4,865 | $21,491.34 | 265,473 | |
| Rahmer Peter | RLAY | See remarks | Dec 27 '24 | Sell | $4.38 | 400 | $1,752.00 | 307,081 |
Latest Relay Therapeutics Inc. News
RLAY Breaking Stock News: Dive into RLAY Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025
MT Newswires
22 days ago
Relay Therapeutics Insider Sold Shares Worth $268,339, According to a Recent SEC Filing
MT Newswires
22 days ago
Relay Therapeutics Insider Sold Shares Worth $362,298, According to a Recent SEC Filing
Insider Monkey
a month ago
Relay Therapeutics Inc (RLAY): AI-Driven Cancer Treatments Backed by Barclays’ $17 Price Target
Simply Wall St.
a month ago
We're Keeping An Eye On Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Rate
GlobeNewswire
a month ago
Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Insider Monkey
2 months ago
Is Relay Therapeutics (RLAY) the Best Biotech Penny Stock to Invest in Now?
Zacks
2 months ago
Relay Therapeutics (RLAY) Moves to Buy: Rationale Behind the Upgrade
Compare RLAY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RLAY Relay Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.